These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

130 related items for PubMed ID: 8860193

  • 1. High plasma prolactin levels after long-term neuroleptic treatment.
    Zelaschi NM, Delucchi GA, Rodriguez JL.
    Biol Psychiatry; 1996 May 15; 39(10):900-1. PubMed ID: 8860193
    [No Abstract] [Full Text] [Related]

  • 2. Atypical antipsychotics: mechanism of action.
    Seeman P.
    Can J Psychiatry; 2002 Feb 15; 47(1):27-38. PubMed ID: 11873706
    [Abstract] [Full Text] [Related]

  • 3. Lack of tolerance to long-term neuroleptic treatment in dopamine tuberoinfundibular system.
    Chouinard G, Annable L, Jones BD, Collu R.
    Acta Psychiatr Scand; 1981 Nov 15; 64(5):353-62. PubMed ID: 6126066
    [Abstract] [Full Text] [Related]

  • 4. Abnormal prolactin elevation in a schizophrenic patient in treatment with quetiapine and mirtazapine. The role of opioid system.
    Orlandi V, Speca A, Salviati M, Biondi M.
    J Clin Psychopharmacol; 2003 Dec 15; 23(6):677-9. PubMed ID: 14624206
    [No Abstract] [Full Text] [Related]

  • 5. Prolactin levels and effects of neuroleptics.
    Brown WA.
    Psychosomatics; 1983 Jun 15; 24(6):569-74, 577-81. PubMed ID: 6136065
    [No Abstract] [Full Text] [Related]

  • 6. Effect of long-term neuroleptic treatment on dopamine tuberoinfundibular system: development of tolerance?
    Naber D, Fischer H, Ackenheil M.
    Commun Psychopharmacol; 1979 Jun 15; 3(1):59-65. PubMed ID: 38032
    [No Abstract] [Full Text] [Related]

  • 7. Plasma prolactin in schizophrenia subjects treated with Seroquel (ICI 204,636).
    Hamner MB, Arvanitis LA, Miller BG, Link CG, Hong WW.
    Psychopharmacol Bull; 1996 Jun 15; 32(1):107-10. PubMed ID: 8927658
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Neuropsychological and conditioned blocking performance in patients with schizophrenia: assessment of the contribution of neuroleptic dose, serum levels and dopamine D2-receptor occupancy.
    Oades RD, Rao ML, Bender S, Sartory G, Müller BW.
    Behav Pharmacol; 2000 Jun 15; 11(3-4):317-30. PubMed ID: 11103886
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. [Sulpiride: a neuroleptic agent of new generation with unique pharmacological qualities and rather wide range of clinical applications].
    Pawłowski L.
    Psychiatr Pol; 1993 Jun 15; 27(2):199-205. PubMed ID: 8104350
    [Abstract] [Full Text] [Related]

  • 16. Changes in blink rates of Nigerian schizophrenics treated with chlorpromazine.
    Adamson TA.
    West Afr J Med; 1995 Jun 15; 14(4):194-7. PubMed ID: 8634222
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Serum prolactin levels following intramuscular chlorpromazine: two- and three-hour response as predictors of six-hour response.
    Busch DA, Fang VS, Meltzer HY.
    Psychiatry Res; 1979 Oct 15; 1(2):153-9. PubMed ID: 45130
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.